NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced after the close of the market on Thursday a commercialization deal with Lamprogen.

Lamprogen, a University of Washington spinout, has granted Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles. The particles can be used in a broad array of assays and research applications including flow cytometry, Bio-Rad said, adding it expects to commercialize the products in 2013.

The deal also grants Bio-Rad access to future technologies developed by Lamprogen.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Futurism writes that gene doping could be the next generation of cheating in sports.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.